A Study Evaluating the Efficacy of Immune Checkpoint Inhibitors for Treating Brain Metastases in Patients with Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Study Evaluating the Efficacy of Immune Checkpoint Inhibitors for Treating Brain Metastases in Patients with Non-Small Cell Lung Cancer (NSCLC)

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Brain metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Nov 2017 New trial record
    • 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top